Full Press Release Details
Vaccitech's VTP-300 induced
sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low
VTP-300 as a monotherapy and in combination
with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent
transient transaminitis.
Meaningful, durable reductions of
Hepatitis B surface antigen (HBsAg) were seen in some patients who received VTP-300 as either a monotherapy or in combination with a
single low dose of nivolumab at the booster dose. Declines were most prominent in patients with lower baseline HBsAg.
All patients who received VTP-300
monotherapy or in combination with low-dose nivolumab and who had a HBsAg decline greater than 0.5 log10 had durable reductions
of HBsAg until the last measurement (up to eight months after last dose).
A robust T cell response against
all encoded antigens, measured by overnight stimulation, was observed following VTP-300 administration, notably for marked CD8+ T cell
predominance, which, to our knowledge, has never been achieved by any other immunotherapeutic.
Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the
discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and
autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from the HBV002 study (NCT04778904),
which is being presented as a poster at the 2022 EASL International Liver CongressTM by Professor Ellie Barnes, Professor
of Hepatology and Experimental Medicine at the University of Oxford.
The updated analysis, with a data cut-off
of May 9th, which now includes 39 patients with at least three months of follow-up, shows that VTP-300 as a monotherapy or in combination
with a single low-dose nivolumab at the time of the booster dose was safely administered with no treatment-related serious adverse events
and two patients with mild, rapidly resolving transaminitis.
In the VTP-300 monotherapy group,
meaningful and durable reductions of HBsAg were seen in all three patients with baseline HBsAg under 50 IU/mL. These three
patients had 0.7, 0.7 and 1.4 log10 declines two months after the last dose of VTP-300. These dramatic declines have
persisted in all three patients at their latest follow-up at five or eight months after the last dose of VTP-300.
For the first eight patients who received
VTP-300 in combination with a single low-dose of nivolumab at the time of the booster dose, the mean reduction in HBsAg was over 1 log10
at six months, an effect that persisted, with a mean decline of 1.15 log10 at eight months after the last dose of VTP-300.
The effect was most prominent in patients with baseline HBsAg lower than 1,000 IU/mL. One patient in this group developed a non-detectable
HBsAg level, which continued eight months after the last dose of VTP-300.
No reductions 1 log10 were
seen in patients who received two doses of MVA-HBV, or in patients who received low-dose nivolumab with both doses of VTP-300. These
two groups were discontinued after interim analysis.
immune system is likely a needed component in achieving durable HBsAg loss that could lead to a functional cure for patients with chronic
hepatitis B (CHB)," said Dr. Henry Chan, Honorary Clinical Professor, Faculty of Medicine, The Chinese University of Hong
Kong. "This exciting initial data supports VTP-300's potential as an immunotherapy that can stimulate an antigen-specific
immune response and could be a critical component of a functional cure regimen. I look forward to following future clinical and combination
developments." Dr. Henry Chan is a scientific advisor to Vaccitech but not directly involved in the HBV002 study.
A robust T cell response against all
encoded antigens (core protein, polymerase and surface antigen), measured by overnight stimulation, was observed following VTP-300 administration,
notable for marked CD8+ T cell predominance.
robust T cell response and marked, durable HBsAg reduction eight months after VTP-300 administration is remarkable," said Thomas
Evans, M.D., Chief Scientific Officer of Vaccitech. "We believe the prominent effect we are observing in patients with lower starting
HBsAg levels supports the collaborative study with Arbutus Biopharma's siRNA, AB-729, in which HBsAg has shown to be lowered below
100 IU/mL in a majority of treated patients."
HBV002 study is complete with 55 patients enrolled. An updated interim analysis for all patients at the six month follow-up timepoint
is expected at the end of 2022.
trial to look at timing of low dose nivolumab and additional doses of the MVA boost component of VTP-300 (NCT05343481) is planned
in multiple countries, with the first patient expected to be dosed in the third quarter of 2022.
of chronic hepatitis B virus (HBV) infection. Fewer than 10% of patients on current standard of care HBV therapies ever achieve distinct,
sustained HBsAg decrease or loss, a state associated with functional cure of the disease. The crux of chronic HBV is the immune system's
inability to clear the virus due to insufficient immune priming and/or aberrant immune tolerance due to large quantities of HBV protein
expression. Many involved in the field believe it makes sense to combine an immune-stimulating agent with an HBV protein-suppressing
agent, to potentially elicit a functional cure to HBV.
Presentation details
Poster Title: Phase 1b/2a
study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed
patients with CHB on nucleos(t)ide analogues
Poster Number: SAT-428
Presenter: Ellie Barnes,
Professor of Hepatology and Experimental Medicine, Nuffield Department of Medicine, University of Oxford
HBV002 is an open-label trial designed
to evaluate the safety, immunogenicity and preliminary efficacy of ChAdOx1-HBV and MVA-HBV (VTP-300), with or without low-dose nivolumab,
in patients with chronic HBV with suppressed HBV DNA on nucleos(t)ide therapy.
As of June 22, 2022, 55 patients
have been enrolled, and no concerning safety signals or vaccine-related serious adverse events have been reported.
Data from a previous interim analysis of HBV002 presented
at the AASLD The Liver Meeting in November 2021 showed that VTP-300 induced antigen specific T cell responses to
all antigens, with elevated responses to core and polymerase, as compared to healthy controls dosed with ChAdOx1-HBV alone in HBV001,
who exhibited a greater response to surface antigen. As in the HBV001 results, T cell responses cross-reactive to Genotype D-specific
peptides were measured in the majority of patients.
VTP-300 is a novel immunotherapy, dosed
in a prime-boost regimen, whereby the immune system is primed with an adenovirus (ChAdOx1) and boosted with a pox virus (MVA). Both vectors
have been modified to improve safety, enhance the immune response they induce and include HBV specific antigens including core, polymerase
and surface antigen. Clinical data generated to date has demonstrated this regimen to be generally safe and well-tolerated, that antigen
specific T cell responses are stimulated to each antigen and there were meaningful reductions in hepatitis B surface antigen when this
regimen is given alone or when given in combination with a low dose of nivolumab at the boost.
About Vaccitech plc.
Vaccitech ("the Company")
is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment
of chronic infectious diseases, cancer, autoimmunity and diseases where the T cell arm of the immune system is believed to play an important
role. The company's proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors
including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax and Syntholytic ).
The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly
higher magnitudes of T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical
stage therapeutic programs to treat solid tumors, chronic viral infections, as well as a few prophylactic viral vaccine programs. Vaccitech
co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide
to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of all milestones and royalty income
received by OUI from AstraZeneca.
Forward Looking Statement
This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including,
without limitation, express or implied statements regarding: the Company's business plans and objectives, including the
clinical trials of ChAdOx1-HBV and the ChAdOx1-HBV/MVA-HBV (VTP-300) and low-dose nivolumab combination, the continued development
of VTP-300 and the potential therapeutic effects and expected patient population of VTP-300. The words "may,"
"will," "could," "would," "should," "expect," "plan
"anticipate," "intend," "believe," "estimate," "predict,"
"project," "future," "potential," "continue" and similar expressions are intended to